- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02103192
Nutrient-Fortified Beverage Study
March 31, 2014 updated by: PepsiCo Global R&D
The objective of this study is to assess the effects of nutrient-fortified beverage on mental energy in healthy human subjects.
Study Overview
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Illinois
-
Addison, Illinois, United States, 60101
- Biofortis Clinical Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject is male or female, 18-70 years of age, inclusive.
- Subject has a body mass index (BMI) ≥17.0 and ≤32.9 kg/m2 at visit 1 (day -14 to -2).
- Subject has no health conditions that would prevent him/her from fulfilling the study requirements as judged by the Investigator on the basis of medical history, and routine laboratory test results.
- Subject is a non-smoker, defined as no tobacco use for ≥6 months prior to visit 1 (day -14 to -2).
- Individual is willing to maintain a habitual diet and physical activity patterns throughout the study period.
- Subject is willing to consume study product and standardized meals.
- Individual is willing to abstain from caffeinated beverages and other caffeine-containing products for 12 h prior to all test visits (visits 2, 3, and 4; days 0, 3, and 6).
- Subject is willing to abstain from alcohol consumption and avoid non-routine vigorous physical activity for 24 h prior to all test visits (visits 2, 3, and 4; days 0, 3, and 6).
- Subject is willing to discontinue any vitamin/mineral or dietary supplements use for 2 weeks prior to visit 2 (day 0) and throughout the study period.
- Subject is a female who is willing to schedule the randomization visit (visit 2, day 0) during the luteal phase of her menstrual cycle, defined as days 15 to the end of the cycle, where day 1 is the first day of menses, where appropriate.
- Subject understands the study procedures and signs forms providing informed consent to participate in the study and authorization for release of relevant protected health information to the study Investigator.
Exclusion Criteria:
- Subject is unable to understand and/or perform required tests and questionnaires (i.e., subjects cannot complete the practice tests, or tasks).
- Subject is color blind.
- Subject has an abnormal laboratory test result of clinical significance, including, but not limited to creatinine ≥1.5 mg/dL and ALT or AST ≥1.5X upper limit of normal at visit 1 (day -14 to -2).
- Subject has a known allergy or sensitivity to study products or any ingredients of the study products, standardized meals/snacks provided.
- Subject has a gastrointestinal condition that could potentially interfere with absorption of the study product (e.g., inflammatory bowel syndrome, celiac disease, history of gastric bypass surgery).
- Subject has diagnosed depression, schizophrenia, or dementia in the last 2 years prior to visit 1 (day -14 to -2).
- Subject has a history or presence of clinically important cardiac (including, but not limited to, atherosclerotic disease, history of myocardial infarction, peripheral arterial disease, and/or stroke), renal, hepatic, endocrine (including type 1 or type 2 diabetes mellitus), pulmonary, biliary, pancreatic, or neurologic disorders.
- Subject has extreme dietary habits (e.g., vegan, Atkins diet, very high protein).
- Subject has uncontrolled hypertension (systolic blood pressure ≥160 mm Hg or diastolic blood pressure ≥100 mm Hg as defined by the blood pressure measured at visit 1, (day -14 to -2). One re-test will be allowed on a separate day prior to visit 2 (day 0) for subjects whose blood pressure exceeds either of these cut points at visit 1.
- Subject has a history or presence of cancer in the prior 2 years, except for non-melanoma skin cancer.
- Subject has signs/symptoms of an active infection of clinical relevance (e.g., urinary tract or respiratory infection). Test visits (visits 2, 3, and 4; days 0, 3, and 6) will be re-scheduled to allow subject to be symptom-free of any type of systemic infection for at least 5 d.
- Subject has recently used antibiotics (within 5 d of any test visit; Appendix 1). Test days (visits 2, 3, and 4; days 0, 3, and 6) will be rescheduled to allow the subject to be free of antibiotic therapy for at least 5 d.
- Subject has a history of use of psychotropic medications within 6 months of visit 2 (day 0) and throughout study period.
- Subject has used any other prescription medications, including over-the-counter medications within 2 weeks of visit 2 (day 0; Appendix 1) and throughout study period.
- Subject has used any over-the-counter or prescription sleep aid products (including dietary supplements) within 2 weeks of visit 2 (day 0) and throughout study period.
- Subject has a diagnosed sleep disorder (e.g., sleep apnea) or occupation where sleep during the overnight hours is irregular (e.g., 3rd shift or overnight workers).
- Subject consumes excessive amounts of caffeine (>4 cups of caffeinated coffee/d or >400 mg caffeine/d from caffeine-containing products).
- Subject is a female, who is pregnant, planning to be pregnant during the study period, lactating, or is of childbearing potential and is unwilling to commit to the use of a medically approved form of contraception throughout the study period. The method of contraception must be recorded in the source document.
- Subject has a recent history of (within 12 months of screening; visit 1, day -14 to -2) or strong potential for alcohol or substance abuse. Alcohol abuse is defined as >14 drinks per week (1 drink = 12 oz beer, 5 oz wine, or 1½ oz distilled spirits).
- Subject has been exposed to any non-registered drug product within 30 d prior to screening.
- Individual has a condition the Investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results or put the person at undue risk.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Control plus low level nutrient fortification
|
|
Experimental: Control plus increasing level nutrient fortification
|
|
Placebo Comparator: Caffeine-free, carbonated soft drink
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The primary outcome is the changes in the ratings in mood, short-term recognition memory, and attention from pre- to post-study product consumption
Time Frame: 0-2 hours
|
The primary outcome is the changes in the ratings from computer administered tasks within the domains of mood, short-term recognition memory, and attention from pre- to post-study product consumption and between treatment conditions
|
0-2 hours
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Plasma nutrient metabolites
Time Frame: 0-7 hours
|
0-7 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2013
Primary Completion (Actual)
March 1, 2014
Study Registration Dates
First Submitted
March 10, 2014
First Submitted That Met QC Criteria
March 31, 2014
First Posted (Estimate)
April 3, 2014
Study Record Updates
Last Update Posted (Estimate)
April 3, 2014
Last Update Submitted That Met QC Criteria
March 31, 2014
Last Verified
March 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PEP-1319
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Normal Controls
-
University of PennsylvaniaNational Institutes of Health (NIH); National Institute on Aging (NIA)Recruiting
-
National Institute of Environmental Health Sciences...RecruitingInflammation | Metabolic Disease | Normal ControlsUnited States
-
Vanderbilt University Medical CenterCompletedObesity | Insulin Resistance | Normal Weight,Healthy ControlsUnited States
-
University of ZurichCompleted
-
Hospices Civils de LyonCompleted
-
Massachusetts General HospitalCompletedHealthy ControlsUnited States
-
University of North Carolina, Chapel HillNational Institute of Environmental Health Sciences (NIEHS)Terminated
-
Centre for Addiction and Mental HealthUniversity Health Network, TorontoRecruiting
-
ElMindA LtdCompletedHealthy ControlsUnited States
Clinical Trials on Anti-Oxidant Drink
-
Derming SRLUniversity of BolognaCompleted
-
Milton S. Hershey Medical CenterNational Institute on Drug Abuse (NIDA)Not yet recruitingTobacco Use | Oxidative Stress
-
Assiut UniversityCompletedAutoimmune Thyroiditis
-
Altitude Physiology ExpeditionsUniversity of EdinburghCompletedAcute Mountain SicknessUnited Kingdom
-
Virginia Polytechnic Institute and State UniversityCompletedCardiovascular Risk FactorUnited States
-
Light Sciences LLCTerminatedMacular Degeneration | Choroidal NeovascularizationUnited States
-
TCI Co., Ltd.Active, not recruiting
-
University of the PacificCompletedCardiovascular DiseasesUnited States
-
Maastricht University Medical CenterTop Institute Food and NutritionCompletedMuscle Loss in ElderlyNetherlands